TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
Détails
Etat: Public
Version: de l'auteur⸱e
ID Serval
serval:BIB_EC7CF00354A2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
Périodique
Lancet Oncology
Collaborateur⸱rice⸱s
EORTC 10994/BIG 1-00 Study Investigators
ISSN
1474-5488 (Electronic)
ISSN-L
1470-2045
Statut éditorial
Publié
Date de publication
2011
Volume
12
Numéro
6
Pages
527-539
Langue
anglais
Notes
Publication types: Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Mots-clé
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Breast Neoplasms/chemistry, Breast Neoplasms/drug therapy, Female, Humans, Middle Aged, Mutation, Neoadjuvant Therapy, Receptor, erbB-2/analysis, Receptors, Estrogen/analysis, Taxoids/administration & dosage, Taxoids/therapeutic use, Tumor Suppressor Protein p53/genetics, Tumor Suppressor Protein p53/physiology
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/10/2011 9:25
Dernière modification de la notice
20/08/2019 17:14
Données d'usage
